Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amoxicillin + sulbactam is a combination antibiotic consisting of amoxicillin, a broad-spectrum beta-lactam (aminopenicillin) antibiotic, and sulbactam, a beta-lactamase inhibitor. Amoxicillin works by binding to penicillin-binding proteins (PBPs), inhibiting bacterial cell wall synthesis and leading to cell death. Sulbactam inhibits bacterial beta-lactamases that would otherwise degrade amoxicillin, thereby extending its spectrum of activity to include many beta-lactamase-producing organisms. This combination is indicated for the treatment of various infections caused by susceptible bacteria, including respiratory tract infections, ear/nose/throat infections, urinary tract infections, skin and soft tissue infections, gynecological infections, and as prophylaxis or treatment in certain surgical situations. It is generally well absorbed orally with good tissue penetration and has a favorable safety profile[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amoxicillin + sulbactam.